Impact of diabetes and its treatment on bone

Clinical Reviews in Bone and Mineral Metabolism

Volumn 7, Issue 3, 2009, Pages 249-260

  Schwartz, Ann V ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Advanced glycation endproducts; Bone mineral density; Bone quality; Diabetes; Fracture; Hyperglycemia; Thiazolidinediones

Indexed keywords

EID: 84905094655     PISSN: 15348644     EISSN: 15590119     Source Type: Journal    
DOI: 10.1007/s12018-009-9049-3     Document Type: Article

References (100)

1. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes-a meta-analysis. Osteoporos Int. 2007;18:427-44. (Pubitemid 46354916)
2. Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol. 2007;166(5):495-505. (Pubitemid 47283633)
3. Schwartz AV, Sellmeyer DE, Ensrud KE, Cauley JA, Tabor HK, Schreiner PJ, et al. Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab. 2001;86:32-8. (Pubitemid 32109771)
4. Bonds DE, Larson JC, Schwartz AV, Strotmeyer ES, Robbins J, Rodriguez BL, et al. Risk of fracture among women with type 2 diabetes: the women's health initiative observational study. J Clin Endocrinol Metab. 2006;91:3404-10. (Pubitemid 44402111)
5. Holmberg AH, Johnell O, Nilsson PM, Nilsson J, Berglund G, Akesson K. Risk factors for fragility fracture in middle age. A prospective population-based study of 33, 000 men and women. Osteoporos Int. 2006;17:1065-77. (Pubitemid 43864859)
6. Melton LJ III, Leibson CL, Achenbach SJ, Therneau TM, Khosla S. Fracture risk in type 2 diabetes: update of a popula-tion- based study. J Bone Miner Res. 2008;23:1334-42. (Pubitemid 352040189)
7. de Liefde I, van der Klift M, de Laet CE, van Daele PL, Hofman A, Pols HA. Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study. Osteoporos Int. 2005;16:1713-20. (Pubitemid 41790880)
8. Strotmeyer ES, Cauley JA, Schwartz AV, Nevitt MC, Resnick HE, Bauer DC, et al. Nontraumatic fracture risk with diabetes mellitus and impaired fasting glucose in older white and black adults: the health, aging, and body composition study. Arch Intern Med. 2005;165:1612-7. (Pubitemid 41124155)
9. Keegan TH, Kelsey JL, Sidney S, Quesenberry CP Jr. Foot problems as risk factors of fractures. Am J Epidemiol. 2002;155:926-31. (Pubitemid 34517849)
10. Vestergaard P, Rejnmark L, Mosekilde L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia. 2005;48:1292-9. (Pubitemid 41186093)
11. Hanley DA, Brown JP, Tenenhouse A, Olszynski WP, Ioannidis G, Berger C, et al. Associations among disease conditions, bone mineral density, and prevalent vertebral deformities in men and women 50 years of age and older: cross-sectional results from the Canadian Multicentre Osteoporosis Study. J Bone Miner Res. 2003;18:784-90. (Pubitemid 36899328)
12. Ensrud KE, Thompson DE, Cauley JA, Nevitt MC, Kado DM, Hochberg MC, et al. Prevalent vertebral deformities predict mortality and hospitalization in older women with low bone mass. Fracture Intervention Trial Research Group. J Am Geriatr Soc. 2000;48:241-9. (Pubitemid 30164205)
13. Yamamoto M, Yamaguchi T, Yamauchi M, Kaji H, Sugimoto T. Diabetic patients have an increased risk of vertebral fractures independent of bone mineral density or diabetic complications. J Bone Miner Res. 2009;24(4):702-9.
14. Nicodemus KK, Folsom AR. Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care. 2001;24:1192-7. (Pubitemid 33716397)
15. Holmberg AH, Nilsson PM, Nilsson JA, Akesson K. The association between hyperglycemia and fracture risk in middle age. A prospective, population-based study of 22, 444 men and 10, 902 women. J Clin Endocrinol Metab. 2008;93:815-22. (Pubitemid 351398558)
16. Leslie WD, Lix LM, Prior HJ, Derksen S, Metge C, O'Neil J. Biphasic fracture risk in diabetes: a population-based study. Bone. 2007;40:1595-601. (Pubitemid 46756425)
17. Reid IR. Relationships between fat and bone. Osteoporos Int. 2008;19:595-606. (Pubitemid 351642171)
18. Schwartz AV, Hillier TA, Sellmeyer DE, Resnick HE, Gregg E, Ensrud KE, et al. Older women with diabetes have a higher risk of falls: a prospective study. Diabetes Care. 2002;25:1749-54. (Pubitemid 41071081)
19. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ. 2009;180:32-9.
20. Bauer DC, Browner WS, Cauley JA, Orwoll ES, Scott JC, Black DM, et al. Factors associated with appendicular bone mass in older women. The Study of Osteoporotic Fractures Research Group. Ann Intern Med. 1993;118:657-65. (Pubitemid 23118035)
21. Orwoll ES, Bauer DC, Vogt TM, Fox KM. Axial bone mass in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med. 1996;124:187-96.
22. Strotmeyer ES, Cauley JA, Schwartz AV, Nevitt MC, Resnick HE, Zmuda JM, et al. Diabetes is associated independently of body composition with BMD and bone volume in older white and black men and women: The Health, Aging, and Body Composition Study. J Bone Miner Res. 2004;19:1084-91. (Pubitemid 41110559)
23. Schwartz AV, Sellmeyer DE, Strotmeyer ES, Tylavsky FA, Feingold KR, Resnick HE, et al. Diabetes and bone loss at the hip in older black and white adults. J Bone Miner Res. 2005;20:596-603. (Pubitemid 40393067)
24. Keegan TH, Schwartz AV, Bauer DC, Sellmeyer DE, Kelsey JL. Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women: the fracture intervention trial. Diabetes Care. 2004;27:1547-53. (Pubitemid 38857424)
25. Cauley JA, Lui LY, Barnes D, Ensrud KE, Zmuda JM, Hillier TA, et al. Successful skeletal aging: a marker of low fracture risk and longevity. The Study of Osteoporotic Fractures (SOF). J Bone Miner Res. 2009;24:134-43.
26. Strotmeyer ES, Boudreau RM, Marshall LM, Schwartz AV, Bauer DC, Barrett-Connor E, et al. Higher bone mineral density loss in older men with diabetes: The Osteoporotic Fractures in Men Study. In: ASBMR 30th Annual Meeting, 2008. Montreal, Canada: ASBMR; 2008.
27. Krakauer JC, McKenna MJ, Buderer NF, Rao DS, Whitehouse FW, Parfitt AM. Bone loss and bone turnover in diabetes. Diabetes. 1995;44:775-82.
28. Berger C, Langsetmo L, Joseph L, Hanley DA, Davison S, Josse RG, et al. Association between change in bone mineral density (BMD) and fragility fracture in women and men. J Bone Miner Res. 2009;24:361-70.
29. Register TC, Lenchik L, Hsu FC, Lohman KK, Freedman BI, BowdenDW,et al. Type 2 diabetes is not independently associated with spinal trabecular volumetric bone mineral density measured by QCT in the Diabetes Heart Study. Bone. 2006;39: 628-33. (Pubitemid 44149275)
30. Melton LJ III, Riggs BL, Leibson CL, Achenbach SJ, Camp JJ, Bouxsein ML, et al. A bone structural basis for fracture risk in diabetes. J Clin Endocrinol Metab. 2008;93:4804-9.
31. Petit M, Paudel ML, Taylor B, Hughes J, Strotmeyer ES, Schwartz AV, et al. Bone mass and strength in older men with type II diabetes: The Osteoporotic Fractures in Men Study. J Bone Miner Res. 2009; in press.
32. Burghardt AJ, Dais KA, Masharani U, Link TM, Majumdar S. In vivo quantification of intra-cortical porosity in human cortical bone using HR-pQCT in patients with type II diabetes. In: ASBMR 30th Annual Meeting, 2008. Montreal, Canada: ASBMR; 2008.
33. Ural A, Vashishth D. Effects of intracortical porosity on fracture toughness in aging human bone: a microCT-based cohesive finite element study. J Biomech Eng. 2007;129:625-31. (Pubitemid 350005823)
34. Lauretani F, Bandinelli S, Griswold ME, Maggio M, Semba R, Guralnik JM, et al. Longitudinal changes in BMD and bone geometry in a population-based study. J Bone Miner Res. 2008;23:400-8. (Pubitemid 351304670)
35. Kelin M, Frost HM. The numbers of bone resorption and formation foci in rib. Henry Ford Hosp Med Bull. 1964;12:527-36.
36. Pei Y, Hercz G, Greenwood C, Segre G, Manuel A, Saiphoo C, et al. Renal osteodystrophy in diabetic patients. Kidney Int. 1993;44:159-64. (Pubitemid 23198039)
37. Carnevale V, Romagnoli E, D'Erasmo E. Skeletal involvement in patients with diabetes mellitus. Diabetes Metab Res Rev. 2004;20:196-204. (Pubitemid 38714317)
38. Suzuki K, Kurose T, Takizawa M, Maruyama M, Ushikawa K, Kikuyama M, et al. Osteoclastic function is accelerated in male patients with type 2 diabetes mellitus: the preventive role of osteoclastogenesis inhibitory factor/osteoprotegerin (OCIF/OPG) on the decrease of bone mineral density. Diabetes Res Clin Pract. 2005;68:117-25. (Pubitemid 40602618)
39. Gerdhem P, Isaksson A, Akesson K, Obrant KJ. Increased bone density and decreased bone turnover, but no evident alteration of fracture susceptibility in elderly women with diabetes mellitus. Osteoporos Int. 2005;16:1506-12. (Pubitemid 41790853)
40. Dobnig H, Piswanger-Solkner JC, Roth M, Obermayer-Pietsch B, Tiran A, Strele A, et al. Type 2 diabetes mellitus in nursing home patients: effects on bone turnover, bone mass, and fracture risk. J Clin Endocrinol Metab. 2006;91:3355-63. (Pubitemid 44402104)
41. Achemlal L, Tellal S, Rkiouak F, Nouijai A, Bezza A, Derouiche el M, et al. Bone metabolism in male patients with type 2 diabetes. Clin Rheumatol. 2005;24:493-6. (Pubitemid 43055041)
42. Seeman E, Delmas PD. Bone quality - the material and structural basis of bone strength and fragility. N Engl J Med. 2006;354:2250-61.
43. Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, et al. Endocrine regulation of energy metabolism by the skeleton. Cell. 2007;130:456-69. (Pubitemid 47208519)
44. Goh SY, Cooper ME. Clinical review: the role of advanced glycation end products in progression and complications of diabetes. J Clin Endocrinol Metab. 2008;93:1143-52. (Pubitemid 351519698)
45. Odetti P, Rossi S, Monacelli F, Poggi A, Cirnigliaro M, Federici M, et al. Advanced glycation end products and bone loss during aging. Ann N Y Acad Sci. 2005;1043:710-7. (Pubitemid 41123964)
46. Yamamoto M, Yamaguchi T, Yamauchi M, Yano S, Sugimoto T. Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab. 2008;93(3):1013-9. (Pubitemid 351398587)
47. Shiraki M, Kuroda T, Tanaka S, Saito M, Fukunaga M, Nakamura T. Nonenzymatic collagen cross-links induced by glycoxidation (pentosidine) predicts vertebral fractures. J Bone Miner Metab. 2008;26:93-100. (Pubitemid 350307997)
48. Schwartz AV, Garnero P, Hillier TA, Sellmeyer DE, Strotmeyer ES, Feingold KR, et al. Pentosidine and increased fracture risk in older adults with type 2 diabetes. J Clin Endocrinol Metab. 2009. doi:10.1210/jc.2008-2498.
49. Wang X, Shen X, Li X, Agrawal CM. Age-related changes in the collagen network and toughness of bone. Bone. 2002;31:1-7. (Pubitemid 34754417)
50. Viguet-Carrin S, Roux JP, Arlot ME, Merabet Z, Leeming DJ, Byrjalsen I, et al. Contribution of the advanced glycation end product pentosidine and of maturation of type I collagen to compressive biomechanical properties of human lumbar vertebrae. Bone. 2006;39:1073-9. (Pubitemid 44528385)
51. Hernandez CJ, Tang SY, Baumbach BM, Hwu PB, Sakkee AN, van der Ham F, et al. Trabecular microfracture and the influence of pyridinium and non-enzymatic glycation-mediated collagen cross-links. Bone. 2005;37:825-32. (Pubitemid 41773493)
52. Saito M, Fujii K, Marumo K. Degree of mineralization-related collagen crosslinking in the femoral neck cancellous bone in cases of hip fracture and controls. Calcif Tissue Int. 2006;79:160-8. (Pubitemid 44440444)
53. Vashishth D, Gibson GJ, Khoury JI, Schaffler MB, Kimura J, Fyhrie DP. Influence of nonenzymatic glycation on biomechanical properties of cortical bone. Bone. 2001;28:195-201. (Pubitemid 32140975)
54. Tang SY, Zeenath U, Vashishth D. Effects of non-enzymatic glycation on cancellous bone fragility. Bone. 2007;40:1144-51. (Pubitemid 46386561)
55. Saito M, Fujii K, Mori Y, Marumo K. Role of collagen enzymatic and glycation induced cross-links as a determinant of bone quality in spontaneously diabetic WBN/Kob rats. Osteoporos Int. 2006;17:1514-23. (Pubitemid 44387486)
56. Hein G, Wiegand R, Lehmann G, Stein G, Franke S. Advanced glycation end-products pentosidine and N{epsilon}-carboxymethyllysine are elevated in serum of patients with osteoporosis. Rheumatology. 2003;42:1242-6. (Pubitemid 37258489)
57. Miyata T, Notoya K, Yoshida K, Horie K, Maeda K, Kurokawa K, et al. Advanced glycation end products enhance osteoclast-induced bone resorption in cultured mouse unfractionated bone cells and in rats implanted subcutaneously with devitalized bone particles. J Am Soc Nephrol. 1997;8:260-70. (Pubitemid 127455881)
58. Valcourt U, Merle B, Gineyts E, Viguet-Carrin S, Delmas PD, Garnero P. Non-enzymatic glycations of bone collagen modify osteoclastic activity and differentiation. J Biol Chem. 2006;282:5691-5703. (Pubitemid 47093757)
59. McCarthy AD, Uemura T, Etcheverry SB, Cortizo AM. Advanced glycation endproducts interfere with integrin-mediated osteoblastic attachment to a type-I collagen matrix. Int J Biochem Cell Biol. 2004;36:840-8. (Pubitemid 38299399)
60. Franke S, Siggelkow H, Wolf G, Hein G. Advanced glycation endproducts influence the mRNA expression of RAGE, RANKL and various osteoblastic genes in human osteoblasts. Arch Physiol Biochem. 2007;113:154-61. (Pubitemid 47547388)
61. Ogawa N, Yamaguchi T, Yano S, Yamauchi M, Yamamoto M, Sugimoto T. The combination of high glucose and advanced glycation end-products (AGEs) inhibits the mineralization of osteoblastic MC3T3-E1 cells through glucose-induced increase in the receptor for AGEs. Horm Metab Res. 2007;39:871-5.
62. Hein G, Weiss C, Lehmann G, Niwa T, Stein G, Franke S. Advanced glycation end product modification of bone proteins and bone remodelling: hypothesis and preliminary immunohistochemical findings. Ann Rheum Dis. 2006;65:101-4. (Pubitemid 41815647)
63. Thrailkill KM, Lumpkin CK Jr, Bunn RC, Kemp SF, Fowlkes JL. Is insulin an anabolic agent in bone? Dissecting the diabetic bone for clues. Am J Physiol Endocrinol Metab. 2005;289: E735-45. (Pubitemid 41504371)
64. Manolagas SC, Almeida M. Gone with the Wnts: {beta}-catenin, TCF, FOXO, and oxidative stress in age-dependent diseases of bone, lipid, and glucose metabolism. Mol Endocrinol. 2007;21:2605-14. (Pubitemid 350035144)
65. Hamada Y, Fujii H, Fukagawa M. Role of oxidative stress in diabetic bone disorder. Bone. 2009. doi:10.1016/j.bone.2009.02.004.
66. Forsen L, Meyer HE, Midthjell K, Edna TH. Diabetes mellitus and the incidence of hip fracture: results from the Nord-Trondelag Health Survey. Diabetologia. 1999;42:920-5. (Pubitemid 29369598)
67. Ivers RQ, Cumming RG, Mitchell P, Peduto AJ. Diabetes and risk of fracture: The Blue Mountains Eye Study. Diabetes Care. 2001;24:1198-203. (Pubitemid 33716398)
68. Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Yano S, Sugimoto T. Combination of obesity with hyperglycemia is a risk factor for the presence of vertebral fractures in type 2 diabetic men. Calcif Tissue Int. 2008;83:324-31.
69. Gregorio F, Cristallini S, Santeusanio F, Filipponi P, Fumelli P. Osteopenia associated with non-insulin-dependent diabetes mellitus: what are the causes? Diabetes Res Clin Pract. 1994;23:43-54. (Pubitemid 24118514)
70. Sayinalp S, Gedik O, Koray Z. Increasing serum osteocalcin after glycemic control in diabetic men. Calcif Tissue Int. 1995;57:422-5.
71. Hosoda H, Fukui M, Nakayama I, Asano M, Kadono M, Hasegawa G, et al. Bone mass and bone resorption in postmenopausal women with type 2 diabetes mellitus. Metabolism. 2008;57:940-5. (Pubitemid 351814686)
72. Okazaki R, Totsuka Y, Hamano K, Ajima M, Miura M, Hirota Y, et al. Metabolic improvement of poorly controlled noninsu-lin- dependent diabetes mellitus decreases bone turnover. J Clin Endocrinol Metab. 1997;82:2915-20. (Pubitemid 27385648)
73. Rosato MT, Schneider SH, Shapses SA. Bone turnover and insulin-like growth factor I levels increase after improved glycemic control in noninsulin-dependent diabetes mellitus. Calcif Tissue Int. 1998;63:107-11. (Pubitemid 28347682)
74. Capoglu I, Ozkan A, Ozkan B, Umudum Z. Bone turnover markers in patients with type 2 diabetes and their correlation with glycosylated haemoglobin levels. J Int Med Res. 2008;36:1392-8.
75. Zhang L, Liu Y, Wang D, Zhao X, Qiu Z, Ji H, et al. Bone biomechanical and histomorphometrical investment in type 2 diabetic Goto-Kakizaki rats. Acta Diabetol. 2009;46(2):119-26.
76. Kawashima Y, Fritton JC, Yakar S, Epstein S, Schaffler MB, Jepsen KJ, et al. Type 2 diabetic mice demonstrate slender long bones with increased fragility secondary to increased osteoclastogenesis. Bone. 2009;44(4):648-55.
77. Reinwald S, Peterson RG, Allen MR, Burr DB. Skeletal changes associated with the onset of type 2 diabetes in the ZDF and ZDSD rodent models. Am J Physiol Endocrinol Metab. 2009;296(4):E765-E774.
78. Prisby R, Swift J, Bloomfield S, Hogan H, Delp M. Altered bone mass, geometry and mechanical properties during the development and progression of type 2 diabetes in the Zucker diabetic fatty rat. J Endocrinol. 2008;199(3):379-388.
79. Bonewald LF, Johnson ML. Osteocytes, mechanosensing and Wnt signaling. Bone. 2008;42:606-15.
80. Villarino ME, Sanchez LM, Bozal CB, Ubios AM. Influence of short-term diabetes on osteocytic lacunae of alveolar bone. A histomorphometric study. Acta Odontol Latinoam. 2006;19:23-8.
81. Balint E, Szabo P, Marshall CF, Sprague SM. Glucose-induced inhibition of in vitro bone mineralization. Bone. 2001;28:21-8. (Pubitemid 32114089)
82. Botolin S, McCabe LR. Chronic hyperglycemia modulates osteoblast gene expression through osmotic and non-osmotic pathways. J Cell Biochem. 2006;99:411-24. (Pubitemid 44435559)
83. Gopalakrishnan V, Vignesh RC, Arunakaran J, Aruldhas MM, Srinivasan N. Effects of glucose and its modulation by insulin and estradiol on BMSC differentiation into osteoblastic lineages. Biochem Cell Biol. 2006;84:93-101.
84. Lipscombe LL, Jamal SA, Booth GL, Hawker GA. The risk of hip fractures in older individuals with diabetes: a population-based study. Diabetes Care. 2007;30:835-41. (Pubitemid 46556575)
85. Volpato S, Leveille SG, Blaum C, Fried LP, Guralnik JM. Risk factors for falls in older disabled women with diabetes: the women's health and aging study. J Gerontol A Biol Sci Med Sci. 2005;60:1539-45. (Pubitemid 43146459)
86. Schwartz AV, Vittinghoff E, Sellmeyer DE, Feingold KR, de Rekeneire N, Strotmeyer ES, et al. Diabetes-related complications, glycemic control, and falls in older adults. Diabetes Care. 2008;31:391-6.
87. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427-43. (Pubitemid 44903747)
88. Kahn SE, Zinman B, Lachin JM, Haffner SM, Herman WH, Holman RR, et al. Rosiglitazone associated fractures in type 2 diabetes: an analysis from ADOPT. Diabetes Care. 2008;31:845-51.
89. Takeda Pharmaceuticals North America. Observation of an increased incidence of fractures in female patients who received long-term treatment with ACTOS® (pioglitazone HCl) tablets for type 2 diabetes mellitus. Takeda Pharmaceuticals North America, Letter to Health Care Providers, March 2007.
90. Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR. Use of thiazolidinediones and fracture risk. Arch Intern Med. 2008;168:820-5. (Pubitemid 351620084)
91. Grey A, Bolland M, Gamble G, Wattie D, Horne A, Davidson J, et al. The peroxisome-proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab. 2007;92:1305-10. (Pubitemid 46556402)
92. Glintborg D, Andersen M, Hagen C, Heickendorff L, Hermann AP. Association of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2008;93:1696-701. (Pubitemid 351656507)
93. Schwartz AV, Sellmeyer DE, Vittinghoff E, Palermo L, Lecka-Czernik B, Feingold KR, et al. Thiazolidinedione use and bone loss in older diabetic adults. J Clin Endocrinol Metab. 2006;91:3349-54. (Pubitemid 44402103)
94. Yaturu S, Bryant B, Jain SK. Thiazolidinediones treatment decreases bone mineral density in type 2 diabetic men. Diabetes Care. 2007;30:1574-6. (Pubitemid 46876524)
95. Lecka-Czernik B, Suva LJ. Resolving the two "bony" faces of PPAR-gamma. PPAR Res. 2006;2006:27489.
96. Grey A. Skeletal consequences of thiazolidinedione therapy. Osteoporos Int. 2008;19:129-37.
97. Wan Y, Chong LW, Evans RM. PPAR-gamma regulates osteoclastogenesis in mice. Nat Med. 2007;13:1496-503.
98. Lazarenko OP, Rzonca SO, Hogue WR, Swain FL, Suva LJ, Lecka-Czernik B. Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone. Endocrinology. 2007;148:2669-80. (Pubitemid 46984815)
99. Sottile V, Seuwen K, Kneissel M. Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone). Calcif Tissue Int. 2004;75:329-37. (Pubitemid 40064235)
100. Holmberg AH, Johnell O, Nilsson PM, Nilsson JA, Berglund G, Akesson K. Risk factors for hip fractures in a middle-aged population: a study of 33, 000 men and women. Osteoporos Int. 2005;16:2185-94. (Pubitemid 41790943)